Enhanced detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using cpg oligonucleotide in combination with pokeweed mitogen and phorbol myristate acetate

Cancer Genetics

Volumn 204, Issue 2, 2011, Pages 77-83

  Muthusamy, Natarajan ^a   Breidenbach, Heather ^b   Andritsos, Leslie ^a   Flynn, Joseph ^a   Jones, Jeffrey ^a   Ramanunni, Asha ^a   Mo, Xiaokui ^b   Jarjoura, David ^b   Byrd, John C ^a   Heerema, Nyla A ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Chromosome; Chronic lymphocytic leukemia; Oligonucleotide

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; INTERLEUKIN 15; INTERLEUKIN 2; PHORBOL 13 ACETATE 12 MYRISTATE; POKEWEED MITOGEN; DIAGNOSTIC AGENT; GNKG168; OLIGODEOXYRIBONUCLEOTIDE;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME HIGH RESOLUTION BANDING ANALYSIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; HUMAN; INTERMETHOD COMPARISON; KARYOTYPING; MAJOR CLINICAL STUDY; MOLECULAR PATHOLOGY; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY ANALYSIS; GENETICS; METHODOLOGY; MIDDLE AGED; SENSITIVITY AND SPECIFICITY;

PHYTOLACCACEAE;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; HUMANS; KARYOTYPING; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED; OLIGODEOXYRIBONUCLEOTIDES; POKEWEED MITOGENS; SENSITIVITY AND SPECIFICITY; TETRADECANOYLPHORBOL ACETATE;

EID: 79958274143     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2010.12.006     Document Type: Article

References (38)

1. Byrd JC, Stilgenbauer S, Flinn IW. Chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2004: 163-183.
2. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48:198-206.
3. Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46:219-234.
4. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840-1847.
5. Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848-1854.
6. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-1916.
7. Byrd JC, Gribben JG, Peterson BL, et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol 2006;24:437-443.
8. Byrd JC, Lin TS, Dalton JT, et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007;109:399-404.
9. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002;100:4325-4336.
10. Byrd JC, Smith L, Hackbarth ML, et al. Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab. Cancer Res 2003;63:36-38.
11. Dierlamm J, Michaux L, Criel A, et al. Genetic abnormalities in chronic lymphocytic leukemia and their clinical and prognostic implications. Cancer Genet Cytogenet 1997;94:27-35.
12. Haferlach C, Dicker F, Schnittger S, et al. Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping. Leukemia 2007;21:2442-2451.
13. Lin TS, Ruppert AS, Johnson AJ, et al. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol 2009;27:6012-6018.
14. Meinhardt G, Wendtner CM, Hallek M. Molecular pathogenesis of chronic lymphocytic leukemia: factors and signaling pathways regulating cell growth and survival. J Mol Med 1999;77: 282-293.
15. Gahrton G, Robert KH, Friberg K, et al. Nonrandom chromosomal aberrations in chronic lymphocytic leukemia revealed by polyclonal B-cell-mitogen stimulation. Blood 1980;56:640-647.
16. Juliusson G, Gahrton G. Abnormal/normal metaphase ratio and prognosis in chronic B-lymphocytic leukemia. Cancer Genet Cytogenet 1985;18:307-313.
17. Juliusson G, Oscier DG, Fitchett M, et al. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med 1990;323:720-724.
18. Juliusson G, Robert KH, Ost A, et al. Prognostic information from cytogenetic analysis in chronic B-lymphocytic leukemia and leukemic immunocytoma. Blood 1985;65:134-141.
19. Chevallier P, Penther D, Avet-Loiseau H, et al. CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukaemia. Br J Haematol 2002;116: 142-150.
20. Reddy KS. Chronic lymphocytic leukaemia profiled for prognosis using a fluorescence in situ hybridisation panel. Br J Haematol 2006;132:705-722.
21. Stilgenbauer S, Dohner K, Bentz M, et al. Molecular cytogenetic analysis of B-cell chronic lymphocytic leukemia. Ann Hematol 1998;76:101-110.
22. Geisler CH, Philip P, Christensen BE, et al. In B-cell chronic lymphocytic leukaemia chromosome 17 abnormalities and not trisomy 12 are the single most important cytogenetic abnormalities for the prognosis: a cytogenetic and immunophenotypic study of 480 unselected newly diagnosed patients. Leuk Res 1997;21:1011-1023.
23. Juliusson G, Oscier D, Juliusson G, et al. Cytogenetic findings and survival in B-cell chronic lymphocytic leukemia. Second IWCCLL compilation of data on 662 patients. Leuk Lymphoma 1991;5:21-25.
24. Decker T, Schneller F, Kronschnabl M, et al. Immunostimulatory CpG-oligonucleotides induce functional high affinity IL-2 receptors on B-CLL cells: costimulation with IL-2 results in a highly immunogenic phenotype. Exp Hematol 2000;28:558-568.
25. Decker T, Schneller F, Sparwasser T, et al. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood 2000;95:999-1006.
26. Dicker F, Schnittger S, Haferlach T, et al. Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: a study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression. Blood 2006;108:3152-3160.
27. Mayr C, Speicher MR, Kofler DM, et al. Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood 2006;107:742-751.
28. Put N, Konings P, Rack K, et al. Improved detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide and interleukin-2 stimulation: a Belgian multicentric study. Genes Chromosomes Cancer 2009;48:843-853.
29. Struski S, Gervais C, Helias C, et al. Stimulation of B-cell lymphoproliferations with CpG-oligonucleotide DSP30 plus IL-2 is more effective than with TPA to detect clonal abnormalities. Leukemia 2009;23:617-619.
30. Cheson BD, Bennett JM, Grever M, et al. National Cancer Instituteesponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990-4997.
31. Shaffer LG, Slovak ML, Campbell LJ, editors. ISCN 2009: an international system for human cytogenetic nomenclature. Basel: Karger; 2009.
32. Breslow N, Clayton D. Approximate inference in generalised linear mixed models. J Am Stat Assoc 1993;88:9-25.
33. Juliusson G. Immunologic and cytogenetic studies improve prognosis prediction in chronic B-lymphocytic leukemia. A multivariate analysis of 24 variables. Cancer 1986;58:688-693.
34. Stockero KJ, Fink SR, Smoley SA, et al. Metaphase cells with normal G-bands have cryptic interstitial deletions in 13q14 detectable by fluorescence in situ hybridization in B-cell chronic lymphocytic leukemia. Cancer Genet Cytogenet 2006;166: 152-156.
35. Buhmann R, Kurzeder C, Rehklau J, et al. CD40L stimulation enhances the ability of conventional metaphase cytogenetics to detect chromosome aberrations in B-cell chronic lymphocytic leukaemia cells. Br J Haematol 2002;118:968-975.
36. Buhmann R, Nolte A, Westhaus D, et al. CD40-activated Bcell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells. Blood 1999;93: 1992-2002.
37. Bauer S, Kirschning CJ, Hacker H, et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci USA 2001;98:9237-9242.
38. Manzel L, Macfarlane DE. CpG-oligodeoxynucleotide-resistant variant of WEHI 231 cells. J Leukoc Biol 1999;66:817-821.